Research programme: T cell receptor engineered T cell therapies - Medigene AG
Latest Information Update: 08 Apr 2024
At a glance
- Originator MediGene AG
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 04 Apr 2024 Medigene receives patent protection for inducible Medigene T cell receptor (iM-TCR) technology in Europe
- 04 Mar 2024 Medigene has a patent for its inducible Medigene T cell receptor (iM-TCR) technology to directly control TCR-T safety and efficacy, in Vivo in Japan
- 14 Jun 2023 Pharmacodynamics data from the in vitro and in vivo studies in solid tumours released by Medigene